Study of Phenoxodiol in Cancer Patients
Author Information
Author(s): Jan B Howes, Paul L de Souza, Leanne West, Li Jiu Huang, Laurence G Howes
Primary Institution: Griffith University
Hypothesis
What are the pharmacokinetics of phenoxodiol following intravenous administration in patients with advanced cancer?
Conclusion
Phenoxodiol has a short plasma half-life, particularly in the free form, leading to a rapid attainment of steady state levels during continuous intravenous infusion.
Supporting Evidence
- Phenoxodiol was administered to six patients with advanced cancer.
- The pharmacokinetics were studied after both a single bolus and continuous infusion.
- The study found that phenoxodiol has a short half-life and high clearance rates.
Takeaway
This study looked at how a new cancer drug, phenoxodiol, behaves in the body after being given through an IV. It found that the drug leaves the body quickly.
Methodology
A single center, open-label pharmacokinetic study involving six patients with metastatic cancer was performed, administering both a single intravenous bolus and a continuous intravenous infusion of phenoxodiol.
Potential Biases
Potential conflicts of interest due to funding and employment relationships with Novogen Pty Ltd.
Limitations
The study involved a small number of patients and examined only a limited dose range of phenoxodiol.
Participant Demographics
Six patients (3 males, 3 females) with metastatic cancer, mean age 61.2 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website